The most frequent mutations include the oncogenic Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutations [1], tumour suppressor Tumour Protein 53 (TP53) inactivating mutations [4], Cyclin-dependent Kinase Inhibitor 2A mutations which lead to dysregulation of the cell cycle [5], and inactivating mutations of the tumour suppressor Deleted in Pancreatic Cancer 4, which occur in approximately 90, 70, 50 and 40% of pancreatic tumours, respectively [6]. The gene discussed is KRAS; the disease is pancreatic neoplasm.